Shopping cart ITEMS
 modern scholarly publishers in the finest tradition
Login Register
Home
Books
Journals
References
A-Z Index
Author Index
For Our Authors
User Area
Shopping Cart
Contact
Electronic Data Center

Critical Reviews™ in Eukaryotic Gene Expression

 

ISSN for PRINT: 1045-4403

Institutional price:

$708.00

Issues per year:

4

For Online Access

Best Paper Award Selection - Editorial Board Site

Add subscription to shopping cart

2004, Volume14

Issue 1&2

  151 pages  

DOI: 10.1615/CritRevEukaryotGeneExpr.v14.i12   

click 'Save as...' here to save XML metadata

Issue price - $338.00  

Add to shopping cart

  • Progress Toward Skeletal Gene Therapy
  • Henry J. Klamut
    Departments of Medicine and Biochemistry, Loma Linda University and the Musculoskeletal Disease Center (151), Jerry L. Pettis Memorial Veterans Administration Medical Center, 11201 Benton Street, Loma Linda, CA 92357

    Shin-Tai Chen
    Departments of Medicine and Biochemistry, Loma Linda University and the Musculoskeletal Disease Center (151), Jerry L. Pettis Memorial Veterans Administration Medical Center, 11201 Benton Street, Loma Linda, CA 92357

    K.-H. William Lau
    Departments of Medicine and Biochemistry, Loma Linda University and the Musculoskeletal Disease Center (151), Jerry L. Pettis Memorial Veterans Administration Medical Center, 11201 Benton Street, Loma Linda, CA 92357

    David J. Baylink
    Departments of Medicine and Biochemistry, Loma Linda University and the Musculoskeletal Disease Center (151), Jerry L. Pettis Memorial Veterans Administration Medical Center, 11201 Benton Street, Loma Linda, CA 92357


    ABSTRACT

    Skeletal gene therapy is an attractive new approach to the treatment of bone disorders. Impressive advances in our knowledge of the molecular genetic basis of skeletal disorders and fracture healing have led to the development of novel therapeutics based on ectopic expression of one or more genes in patient cells that can influence repair or regenerative processes in bone. Although still a relatively immature field, proof-of-principle for enhanced bone formation through skeletal gene therapy has already been established. The challenge now is to more precisely define optimal cellular targets and therapeutic genes, and to develop safe and efficient ways to deliver therapeutic genes to target cells. In this review, we will highlight some of the exciting advances that have been made in skeletal gene therapy in recent years, with a focus on treatment of localized skeletal lesions. Strengths and weaknesses of current approaches will be discussed, as will strategies for improved safety and therapeutic outcome in the future. Skeletal gene therapy can have an enormous impact on patient care. The next 5 years will present us with unparalleled opportunities to develop more effective therapeutic strategies and overcome obstacles presented by current gene transfer technologies.

    DOI: 10.1615/CritRevEukaryotGeneExpr.v14.i12.60

    Download article, 48 pages

    Article price - $85.00  

    Add to shopping cart

    << Previous article   Next article >>

    Designed by offsiteteam Designed by offsiteteam Designed by offsiteteam
    Begell House Inc.
    50 Cross Highway,
    Redding, CT 06896
    TEL (203) 938 1300
    FAX (203) 938 1304
    orders@begellhouse.com